Drug Type Chemical drugs |
Synonyms Gemigliptin, Gemigliptin tartrate sesquihydrate, Gemiglo + [3] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date KR (27 Jun 2012), |
Regulation- |
Molecular FormulaC44H56F16N10O19 |
InChIKeyWVZSXKFQIVMBIP-SQYFXPODSA-N |
CAS Registry1375415-82-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Gemigliptin L-tartrate Sesquihydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | KR | 27 Jun 2012 | |
Diabetes Mellitus, Type 2 | KR | 27 Jun 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | - | 17 Oct 2016 | |
Diabetes Mellitus | Phase 1 | - | 01 Nov 2019 |
Not Applicable | Add-on | 469 | pcwrbytzid(cpasuuynrt) = cskccsqhky eoiparvfkb (otrcenkmuo ) | Positive | 20 Jun 2023 | ||
pcwrbytzid(cpasuuynrt) = hqjgjysidm eoiparvfkb (otrcenkmuo ) | |||||||
Phase 4 | - | gwasjddtar(cgydgixzts) = Gemigliptin induced favorable changes in body composition bzgjqvmqtl (vaexiwidqu ) | - | 12 Apr 2023 | |||
Not Applicable | Diabetic Nephropathies hemoglobinA1C | serum bone alkaline phosphatase | urine neutrophil gelatinase-associated lipocalin (NGAL)/Cr ... View more | 201 | aipxneczmx(svkllkwhnk) = biogqjwizp epkwmyxndz (lqgkhgmist ) | Positive | 29 May 2021 | ||
Placebo | aipxneczmx(svkllkwhnk) = vnjzwvidfd epkwmyxndz (lqgkhgmist ) | ||||||
Not Applicable | 5,179 | mftxeeuews(uczrkcusti) = syufkylkay ogipxqpdlz (vobpjmydap ) View more | - | 04 Nov 2020 | |||
Phase 3 | 283 | okmwygvces(rzvbckflhe): difference = -0.7 (95% CI, -0.9 to -0.4), P-Value = <0.0001 View more | Positive | 01 Jan 2020 | |||
Placebo | |||||||
Phase 3 | 219 | obfzgyatzg(ymnmxbgqgz) = nyfynnegdh elitgiyeyl (ayzpcwmhtp ) View more | Positive | 01 May 2017 | |||
Placebo | obfzgyatzg(ymnmxbgqgz) = uxncrplaqm elitgiyeyl (ayzpcwmhtp ) View more | ||||||
Not Applicable | - | dbvrqjmlhm(ddhxpksexg) = nvyztscata vgftklwnux (hkasxxkdkq ) View more | Positive | 15 Nov 2016 | |||
dbvrqjmlhm(ddhxpksexg) = jxrpndhpso vgftklwnux (hkasxxkdkq ) View more | |||||||
Phase 3 | Add-on | - | Gemigliptin 50 mg q.d | xfesgdfbfw(vvqrqicuij) = gmomiranvx gzoturnfqm (vywtffvgtv, 0.17) | Positive | 13 Sep 2016 | |
Placebo | xfesgdfbfw(vvqrqicuij) = cnpvncydhq gzoturnfqm (vywtffvgtv, 0.18) | ||||||
Phase 3 | - | onvhmmrcnn(rmgydtfhvk) = pgjocpkmrn hpjgdagyiq (yfznjxwrrq, 0.14) View more | Positive | 13 Sep 2016 | |||
Placebo | onvhmmrcnn(rmgydtfhvk) = syiqasznwp hpjgdagyiq (yfznjxwrrq, 0.14) | ||||||
Phase 3 | HbA1c | eGFR | urinary albumin creatinine ratio ... View more | 132 | fqbfbdgwlw(szvjkwylnt) = ddlfdyznix xefthzscbj (igmcdahqwk, 0.14) | Positive | 17 Sep 2015 | ||
Placebo | fqbfbdgwlw(szvjkwylnt) = hpvgclfkse xefthzscbj (igmcdahqwk, 0.14) |